Development of a porous layer-by-layer microsphere with branched aliphatic hydrocarbon porogens
Copyright © 2022 Elsevier Inc. All rights reserved..
Porous polymer microspheres are employed in biotherapeutics, tissue engineering, and regenerative medicine. Porosity dictates cargo carriage and release that are aligned with the polymer physicochemical properties. These include material tuning, biodegradation, and cargo encapsulation. How uniformity of pore size affects therapeutic delivery remains an area of active investigation. Herein, we characterize six branched aliphatic hydrocarbon-based porogen(s) produced to create pores in single and multilayered microspheres. The porogens are composed of biocompatible polycaprolactone, poly(lactic-co-glycolic acid), and polylactic acid polymers within porous multilayered microspheres. These serve as controlled effective drug and vaccine delivery platforms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Nanomedicine : nanotechnology, biology, and medicine - 48(2023) vom: 15. Feb., Seite 102644 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shahjin, Farah [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2023 Date Revised 29.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nano.2022.102644 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350610835 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350610835 | ||
| 003 | DE-627 | ||
| 005 | 20231226045403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nano.2022.102644 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350610835 | ||
| 035 | |a (NLM)36549555 | ||
| 035 | |a (PII)S1549-9634(22)00130-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shahjin, Farah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a porous layer-by-layer microsphere with branched aliphatic hydrocarbon porogens |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2023 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Porous polymer microspheres are employed in biotherapeutics, tissue engineering, and regenerative medicine. Porosity dictates cargo carriage and release that are aligned with the polymer physicochemical properties. These include material tuning, biodegradation, and cargo encapsulation. How uniformity of pore size affects therapeutic delivery remains an area of active investigation. Herein, we characterize six branched aliphatic hydrocarbon-based porogen(s) produced to create pores in single and multilayered microspheres. The porogens are composed of biocompatible polycaprolactone, poly(lactic-co-glycolic acid), and polylactic acid polymers within porous multilayered microspheres. These serve as controlled effective drug and vaccine delivery platforms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Layer-by-layer | |
| 650 | 4 | |a Poly(glycolide-co-lactide) | |
| 650 | 4 | |a Poly(ε-caprolactone) | |
| 650 | 4 | |a Polylactide | |
| 650 | 4 | |a Porogens | |
| 650 | 4 | |a Porous microspheres | |
| 650 | 4 | |a Solvent evaporation | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Hydrocarbons |2 NLM | |
| 700 | 1 | |a Patel, Milankumar |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Mahmudul |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Jacob D |e verfasserin |4 aut | |
| 700 | 1 | |a Islam, Farhana |e verfasserin |4 aut | |
| 700 | 1 | |a Ashaduzzaman, Md |e verfasserin |4 aut | |
| 700 | 1 | |a Nayan, Mohammad Ullah |e verfasserin |4 aut | |
| 700 | 1 | |a Subramaniam, Mahadevan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, You |e verfasserin |4 aut | |
| 700 | 1 | |a Andreu, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Gendelman, Howard E |e verfasserin |4 aut | |
| 700 | 1 | |a Kevadiya, Bhavesh D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine : nanotechnology, biology, and medicine |d 2005 |g 48(2023) vom: 15. Feb., Seite 102644 |w (DE-627)NLM16062021X |x 1549-9642 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2023 |g day:15 |g month:02 |g pages:102644 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nano.2022.102644 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2023 |b 15 |c 02 |h 102644 | ||